Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study
Sisinni et al.,
Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The..,
International Journal of Cardiology, doi:10.1016/j.ijcard.2021.09.058
Retrospective 984 COVID-19 patients, 253 taking aspirin prior to admission, showing lower risk of respiratory support upgrade with treatment.
risk of death, 7.1% higher, RR 1.07, p = 0.65, treatment 93 of 253 (36.8%), control 251 of 731 (34.3%).
|
risk of death or respiratory support upgrade, 30.3% lower, RR 0.70, p = 0.01, treatment 253, control 731, multivariate.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Sisinni et al., 4 Oct 2021, retrospective, Italy, peer-reviewed, 18 authors.
Abstract: Journal Pre-proof
Pre-admission acetylsalicylic acid therapy and impact on inhospital outcome in COVID-19 patients: The ASA-CARE study
Antonio Sisinni, Luca Rossi, Antonio Battista, Enrico Poletti,
Federica Battista, Rosa Alessia Battista, Alessandro Malagoli,
Andrea Biagi, Alessia Zanni, Concetta Sticozzi, Greta Comastri,
Massimiliano M. Marrocco-Trischitta, Alberto Monello, Alberto
Margonato, Francesco Bandera, Pasquale Vergara, Marco Guazzi,
Cosmo Godino
PII:
S0167-5273(21)01499-6
DOI:
https://doi.org/10.1016/j.ijcard.2021.09.058
Reference:
IJCA 29821
To appear in:
International Journal of Cardiology
Received date:
4 July 2021
Revised date:
26 September 2021
Accepted date:
28 September 2021
Please cite this article as: A. Sisinni, L. Rossi, A. Battista, et al., Pre-admission
acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The
ASA-CARE study, International Journal of Cardiology (2021), https://doi.org/10.1016/
j.ijcard.2021.09.058
This is a PDF file of an article that has undergone enhancements after acceptance, such
as the addition of a cover page and metadata, and formatting for readability, but it is
not yet the definitive version of record. This version will undergo additional copyediting,
typesetting and review before it is published in its final form, but we are providing this
version to give early visibility of the article. Please note that, during the production
process, errors may be discovered which could affect the content, and all legal disclaimers
that apply to the journal pertain.
© 2021 Published by Elsevier B.V.
Journal Pre-proof
Pre-admission Acetylsalicylic Acid Therapy and Impact on In-hospital Outcome in
COVID-19 patients: the ASA-CARE study.
Antonio Sisinni,1 MD, Luca Rossi,2 MD, Antonio Battista,3 MD, Enrico Poletti,4 MD, Federica Battista,5 MD,
Rosa Alessia Battista,6 MD, Alessandro Malagoli,7 MD, Andrea Biagi,8 MD, Alessia Zanni,9 MD, Concetta
Sticozzi,10 MD, Greta Comastri,11 MD, Massimiliano M Marrocco-Trischitta,12 MD, Alberto Monello,13 MD,
Alberto Margonato,14 MD, Francesco Bandera,15 MD, Pasquale Vergara,16 MD, Marco Guazzi*,17 MD, Cosmo
Godino*,18 MD.
1
Jo
ur
na
lP
re
-p
ro
of
Cardiology Unit, IRCCS Policlinico San Donato, Milan, Italy. Università degli studi di Milano, Milan, Italy. This author takes
responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
2
Division of Cardiology, Cardiovascular and Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. This author
takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
3
Emergency Department, Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy. This author takes responsibility
for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
4
Cardiology Unit, IRCCS Policlinico San Donato, Milan, Italy. Università degli studi di Milano, Milan, Italy. This author takes
responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
5
Università degli studi di Pavia, Pavia, Italy. This author takes responsibility for all aspects of the reliability and freedom from bias
of the data presented and their discussed interpretation.
6
i
i Vita-Salute San Raffaele, Milano, Italy. This author takes..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit